Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: Postmarketing analysis from the RADAR ("Research on Adverse Drug events And Reports") program.
J Am Acad Dermatol
; 79(4): 777-778, 2018 Oct.
Article
in En
| MEDLINE
| ID: mdl-29920313
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Inflammatory Bowel Diseases
/
Adverse Drug Reaction Reporting Systems
/
Antibodies, Monoclonal, Humanized
/
Antibodies, Monoclonal
Type of study:
Etiology_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
/
Male
Country/Region as subject:
America do norte
/
Oceania
Language:
En
Journal:
J Am Acad Dermatol
Year:
2018
Document type:
Article
Country of publication:
United States